MHRAsafety guidance72% confidence
Guidance: Clinical trials for medicines: roles and responsibilities
Source: MHRA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Daiichi Sankyo.
Regulatory Analysis
Which professions can act as an investigator, training and experience expectations, provision of medical support and delegation of activities.
Supporting Context
- Therapeutic area
- Cardiovascular · Atherosclerosis
- Sub-indication
- General
Related signal: Daiichi Sankyo Trials Triple Therapy for Coronary Atherosclerosis Without Events